4D Molecular Therapeutics (FDMT) Accumulated Expenses (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Accumulated Expenses data on file, last reported at $6.2 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $6.2 million, down 61.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.2 million (down 61.46% YoY), and the FY2025 annual result was $26.9 million, up 42.42% from the prior year.
• Accumulated Expenses retreated to $6.2 million in Q1 2026 per FDMT's latest filing, from $26.9 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $26.9 million in Q4 2025 and troughed at $2.9 million in Q1 2022.
• A 5-year average of $10.7 million and a median of $6.2 million in 2026 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2025 and 2026: Accumulated Expenses soared 258.79% in 2025, then slumped 61.46% in 2026.
• A 5-year view of Accumulated Expenses shows it stood at $5.7 million in 2022, then surged by 111.18% to $12.0 million in 2023, then jumped by 57.06% to $18.9 million in 2024, then jumped by 42.42% to $26.9 million in 2025, then tumbled by 76.77% to $6.2 million in 2026.
• Business Quant data shows FDMT's Accumulated Expenses at $6.2 million in Q1 2026, $26.9 million in Q4 2025, and $24.2 million in Q3 2025.